Burlington, Massachusetts-based scPharmaceuticals ( NASDAQ: SCPH ) announced on Tuesday that the data from a Phase 2 trial were supportive of its experimental hear failure therapy Furoscix compared to a “treatment as usual” approach.
The AT HOME-HF Pilot study was designed to evaluate Furoscix against “treatment as usual” in patients with chronic heart failure patients who present in the clinic with worsening congestion and requiring augmented diuresis. The 51-subject study was not powered for statistical significance.
The data from the multicenter, randomized study, favored the study drug versus “treatment as usual” for the primary endpoint and all secondary endpoints.
Highlights of the results include a 37% reduction in the risk of a heart failure hospitalization in those who received Furoscix compared to those in the “treatment as usual” arm at day 30.
In terms of safety, 11 subjects had experienced treatment-related adverse events including on serious adverse event (dehydration) that was possibly related to Furoscix.
Notably, one patient in the Furoscix group died which according to the investigator was not related to the experimental drug.
For further details see:
scPharma says key goals in mid-stage study favored heart failure therapy